Parathyroid hormone is associated with the LV mass after aortic valve replacement

Heart

Volumn 100, Issue 23, 2014, Pages 1859-1864

  Laflamme, Marie Hélène ^a   Mahjoub, Haifa ^b   Mahmut, Ablajan ^a   Boulanger, Marie Chloé ^a   Larose, Eric ^b   Pibarot, Philippe ^b   Mathieu, Patrick ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; PTH PROTEIN, HUMAN; VITAMIN D;

AGED; AORTA VALVE REPLACEMENT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AORTA VALVE; BLOOD; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HEART VALVE REPLACEMENT; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; STATISTICAL MODEL; SURGERY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE; BIOLOGICAL MARKERS; CALCIUM; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GLOMERULAR FILTRATION RATE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; LINEAR MODELS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PHOSPHATES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VITAMIN D;

EID: 84922394416     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305837     Document Type: Article

References (30)

1. Lund O, Emmertsen K, Dorup I, et al. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J 2003;24:1437-46.
2. Monrad ES, Hess OM, Murakami T, et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 1988;77:1345-55.
3. Dumesnil JG, Pibarot P. Prosthesis-patient mismatch: an update. Curr Cardiol Rep 2011;13:250-7.
4. Pibarot P, Dumesnil JG, Leblanc MH, et al. Changes in left ventricular mass and function after aortic valve replacement: a comparison between stentless and stented bioprosthetic valves. J Am Soc Echocardiogr 1999;12:981-7.
5. Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:2054-60.
6. van Ballegooijen AJ, Visser M, Kestenbaum B, et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). Am J Cardiol 2013;111:418-24.
7. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011;58:1433-41.
8. Deo R, Katz R, Shlipak MG, et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension 2011;58:1021-8.
9. Lavie CJ, Dinicolantonio JJ, O'Keefe JH, et al. Vitamin D status, left ventricular geometric abnormalities and cardiovascular disease. J Intern Med 2013;273:246-8.
10. Lavie CJ, Dinicolantonio JJ, Milani RV, et al. Vitamin D and cardiovascular health. Circulation 2013;128:2404-6.
11. Ferreira JC, Brum PC, Mochly-Rosen D. betaIIPKC and epsilonPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2011;51:479-84.
12. Hekimian G, Boutten A, Flamant M, et al. Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patients - the COFRASA study. Eur Heart J 2013;34:1915-22.
13. Mahjoub H, Mathieu P, Senechal M, et al. ApoB/ApoA-I ratio is associated with increased risk of bioprosthetic valve degeneration. J Am Coll Cardiol 2013;61:752-61.
14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
15. de SG, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995;25:1056-62.
16. Cramariuc D, Cioffi G, Rieck AE, et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging 2009;2:390-9.
17. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54:1003-11.
18. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013;98:E1283-304.
19. Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J 2011;162:331-9.
20. Lindman BR, Stewart WJ, Pibarot P, et al. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. JACC Cardiovasc Interv 2014;7:662-73.
21. Mohty D, Dumesnil JG, Echahidi N, et al. Impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: influence of age, obesity, and left ventricular dysfunction. J Am Coll Cardiol 2009;53:39-47.
22. Norenstedt S, Pernow Y, Brismar K, et al. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol 2013;169:795-804.
23. Cha H, Jeong HJ, Jang SP, et al. Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med 2010;42:61-8.
24. Cozzolino M, Mehmeti F, Ciceri P, et al. The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control. Int J Nephrol 2011;2011:269060.
25. Tomaschitz A, Pilz S, Ritz E, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010;411:1354-60.
26. Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol 2005;46:291-8.
27. Capoulade R, Clavel MA, Dumesnil JG, et al. Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial. JACC Cardiovasc Imaging 2013;6:165-74.
28. Iwata S, Hyodo E, Yanagi S, et al. Parathyroid hormone and systolic blood pressure accelerate the progression of aortic valve stenosis in chronic hemodialysis patients. Int J Cardiol 2013;163:256-9.
29. Linhartova K, Veselka J, Sterbakova G, et al. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008;72:245-50.
30. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84.